Investigating the NeuroPRotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): a Randomised, Placebo-Controlled Trial
Between July 2017 and September 2019, 43 participants received omega-3 (n=21) or placebo (n=22) supplements. All participants, except for two assigned to placebo, completed the trial. At day 180, the estimated increase in CNFL in the omega-3 group, compared to placebo, was 2.70 mm/mm2 (95%CI: 1.64-3.75). The Omega-3 Index increased relative to placebo (3.3%; 95%CI: 2.4-4.2). There were no differences in most small or large nerve fibre functional parameters. Adverse events were similar between groups.In conclusion, this randomised controlled trial found that long-chain omega-3 supplements impart corneal neuroregenerative effects in type 1 diabetes, indicating a role in modulating peripheral nerve health.